Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Field Trip Health Ltd. stock logo
FTRP
Field Trip Health
C$0.00
C$0.93
▼
C$7.75
C$12.68MN/A36,819 shs97,451 shs
KDA Group Inc. stock logo
KDA
KDA Group
C$0.07
-12.5%		C$0.07
C$0.06
▼
C$0.30
C$16.45M-0.30032888,766 shs9,000 shs
Nova Leap Health Corp. stock logo
NLH
Nova Leap Health
C$0.52
-10.3%		C$0.46
C$0.26
▼
C$0.60
C$45.40M1.75169427,281 shs3,640 shs
Synthetic Biologics, Inc. stock logo
SYN
Synthetic Biologics
$0.00
$0.97
▼
$4.56
$16.16M1.38197,338 shs57,700 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Field Trip Health Ltd. stock logo
FTRP
Field Trip Health
0.00%0.00%0.00%0.00%0.00%
KDA Group Inc. stock logo
KDA
KDA Group
0.00%-15.79%+33.33%0.00%-68.63%
Nova Leap Health Corp. stock logo
NLH
Nova Leap Health
+1.75%+9.43%+52.63%+68.12%+81.25%
Synthetic Biologics, Inc. stock logo
SYN
Synthetic Biologics
0.00%0.00%0.00%0.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Field Trip Health Ltd. stock logo
FTRP
Field Trip Health
C$0.00
C$0.93
▼
C$7.75
C$12.68MN/A36,819 shs97,451 shs
KDA Group Inc. stock logo
KDA
KDA Group
C$0.07
-12.5%		C$0.07
C$0.06
▼
C$0.30
C$16.45M-0.30032888,766 shs9,000 shs
Nova Leap Health Corp. stock logo
NLH
Nova Leap Health
C$0.52
-10.3%		C$0.46
C$0.26
▼
C$0.60
C$45.40M1.75169427,281 shs3,640 shs
Synthetic Biologics, Inc. stock logo
SYN
Synthetic Biologics
$0.00
$0.97
▼
$4.56
$16.16M1.38197,338 shs57,700 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Field Trip Health Ltd. stock logo
FTRP
Field Trip Health
0.00%0.00%0.00%0.00%0.00%
KDA Group Inc. stock logo
KDA
KDA Group
0.00%-15.79%+33.33%0.00%-68.63%
Nova Leap Health Corp. stock logo
NLH
Nova Leap Health
+1.75%+9.43%+52.63%+68.12%+81.25%
Synthetic Biologics, Inc. stock logo
SYN
Synthetic Biologics
0.00%0.00%0.00%0.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Field Trip Health Ltd. stock logo
FTRP
Field Trip Health
0.00
N/AN/AN/A
KDA Group Inc. stock logo
KDA
KDA Group
0.00
N/AN/AN/A
Nova Leap Health Corp. stock logo
NLH
Nova Leap Health
0.00
N/AN/AN/A
Synthetic Biologics, Inc. stock logo
SYN
Synthetic Biologics
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Field Trip Health Ltd. stock logo
FTRP
Field Trip Health
C$4.86M0.00N/A0.98C$1.15 per share0.00
KDA Group Inc. stock logo
KDA
KDA Group
C$419.13K39.26C$0.01 per share5.00C$0.08 per share0.88
Nova Leap Health Corp. stock logo
NLH
Nova Leap Health
C$33.60M1.35C$0.05 per share9.62C$0.22 per share2.34
Synthetic Biologics, Inc. stock logo
SYN
Synthetic Biologics
N/AN/AN/AN/A$4.95 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Field Trip Health Ltd. stock logo
FTRP
Field Trip Health
N/A-C$0.89N/AN/AN/AN/AN/AN/AN/A
KDA Group Inc. stock logo
KDA
KDA Group
-C$1.73M-C$0.03N/AN/AN/A5,414.15%-15.93%-11.56%N/A
Nova Leap Health Corp. stock logo
NLH
Nova Leap Health
-C$300.30KC$0.0234.67N/AN/A3.99%6.95%2.77%N/A
Synthetic Biologics, Inc. stock logo
SYN
Synthetic Biologics
-$14.27M-$1.21N/AN/AN/AN/A-26.14%-22.74%N/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Field Trip Health Ltd. stock logo
FTRP
Field Trip Health
N/AN/AN/AN/AN/A
KDA Group Inc. stock logo
KDA
KDA Group
N/A6.19%N/AN/AN/A
Nova Leap Health Corp. stock logo
NLH
Nova Leap Health
N/AN/AN/AN/AN/A
Synthetic Biologics, Inc. stock logo
SYN
Synthetic Biologics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Field Trip Health Ltd. stock logo
FTRP
Field Trip Health
43.39
8.20
7.70
KDA Group Inc. stock logo
KDA
KDA Group
7.36
2.10
0.35
Nova Leap Health Corp. stock logo
NLH
Nova Leap Health
22.94
0.70
1.13
Synthetic Biologics, Inc. stock logo
SYN
Synthetic Biologics
N/A
4.14
4.14

Institutional Ownership

CompanyInstitutional Ownership
Field Trip Health Ltd. stock logo
FTRP
Field Trip Health
N/A
KDA Group Inc. stock logo
KDA
KDA Group
N/A
Nova Leap Health Corp. stock logo
NLH
Nova Leap Health
0.00%
Synthetic Biologics, Inc. stock logo
SYN
Synthetic Biologics
74.38%

Insider Ownership

CompanyInsider Ownership
Field Trip Health Ltd. stock logo
FTRP
Field Trip Health
N/A
KDA Group Inc. stock logo
KDA
KDA Group
25.51%
Nova Leap Health Corp. stock logo
NLH
Nova Leap Health
40.77%
Synthetic Biologics, Inc. stock logo
SYN
Synthetic Biologics
2.15%
CompanyEmployeesShares OutstandingFree FloatOptionable
Field Trip Health Ltd. stock logo
FTRP
Field Trip Health
10411.63 millionN/ANot Optionable
KDA Group Inc. stock logo
KDA
KDA Group
3,100235.05 millionN/ANot Optionable
Nova Leap Health Corp. stock logo
NLH
Nova Leap Health
N/A87.31 millionN/ANot Optionable
Synthetic Biologics, Inc. stock logo
SYN
Synthetic Biologics
1615.84 million15.50 millionNot Optionable

Recent News About These Companies

Cell Line Development: A Story of Innovation in Biologics and Cell-Based Therapies
August 26, 2026  |  technologynetworks.comT
Protein Design & Engineering Market Global Report 2026: Evaluating AI Platforms, Rational Design, Directed Evolution, and Strategies of Lonza, Thermo Fisher, GenScript, and ...
August 19, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/protein-design-engineering-market-global-142800364.html
Isto Biologics Strengthens its Bone Graft Substitutes Platform with the Acquisition of NovaBone
August 4, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/isto-biologics-strengthens-bone-graft-144000179.html
Vivex Biologics Launches VIA Linx™, a Novel Self-Assembling Synthetic Peptide Matrix, Expanding its Portfolio of Advanced Wound Care Solutions
July 21, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/vivex-biologics-launches-via-linx-a-novel-self-assembling-synthetic-peptide-matrix-expanding-its-portfolio-of-advanced-wound-care-solutions-1036345718
Computational design drives new generation of synthetic promoters
March 27, 2026  |  drugtargetreview.comD
Gene Synthesis Market Comprehensive Industry Analysis, Trends, and Future Outlook
February 25, 2026  |  pharmiweb.comP
6 ways biologics is advancing in spine
February 19, 2026  |  beckersspine.comB
Stopping Biologics Before Surgery May Raise Flare Risk in RA
January 27, 2026  |  rheumatologyadvisor.comR
Study Shows NanoFuse(R) Superiority: Why Bioactive Glass-DBM Composites Outperform DBM and Bioactive Glass Alone
January 26, 2026  |  marketwatch.comhttps://www.marketwatch.com/press-release/study-shows-nanofuse-r-superiority-why-bioactive-glass-dbm-composites-outperform-dbm-and-bioactive-glass-alone-9d78ab86
MTF Biologics and Kolosis BIO Launch New Solution for Orthopedic and Spinal Surgeries: Summit Matrix™
January 15, 2026  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/mtf-biologics-kolosis-bio-launch-180500270.html
MTF Biologics and Kolosis BIO Launch New Solution for Orthopedic and Spinal Surgeries: Summit Matrix(TM)
January 15, 2026  |  marketwatch.comhttps://www.marketwatch.com/press-release/mtf-biologics-and-kolosis-bio-launch-new-solution-for-orthopedic-and-spinal-surgeries-summit-matrix-tm-130fb300
Asimov and AGC Biologics Team Up to Provide a Cost-Effective, Simplified, and Secure Manufacturing Approach for Viral Vector Production
January 13, 2026  |  pharmiweb.comP
4 orthobiologics updates
December 18, 2025  |  beckersspine.comB
Exposure to Some DMARDs in Fathers-to-Be Tied to Birth Risks
December 2, 2025  |  medscape.comM
Relapse in Juvenile Idiopathic Arthritis After Stopping DMARDs: Key Factors Found
December 1, 2025  |  medscape.comM
Constructive Bio and RxCelerate partner to develop biologic therapeutic candidates
November 19, 2025  |  businessweekly.co.ukB
RA Onset Age Doesn’t Affect Non-TNF Agents’ Infection Risk
October 29, 2025  |  medscape.comM
Aurora Spine Launches New Biologics Portfolio
October 28, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/aurora-spine-launches-new-biologics-portfolio-1035434970
Wound Care Biologics Market Size Worth USD 11.22 Billion by 2034
October 27, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/wound-care-biologics-market-size-071500629.html
Study assesses SI joint outcomes between surgeons, pain physicians
October 21, 2025  |  beckersspine.comB

Media Sentiment Over Time

Top Headlines

View All Headlines
NVIDIA logo displayed on a computer chip surrounded by illuminated green circuit board traces.
NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
By Thomas Hughes | August 11, 2026
A quantum computing processor glows inside a gold-plated dilution refrigerator in a research laboratory.
The Quantum Race Is Heating Up—And 2 Small Players Stand Out
By Nathan Reiff | August 17, 2026
The Metals Company logo displayed over an image of polymetallic nodules on the seafloor with sea stars.
The Metals Company’s Big Bet Now Comes Down to a License
By Thomas Hughes | August 16, 2026
Workday logo displayed on an office wall, with desks and computer monitors visible in the background.
From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens
By Thomas Hughes | August 29, 2026
Riot Platforms logo overlaid on an aerial view of a large data center facility with adjacent electrical substation.
Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
By Jeffrey Neal Johnson | August 13, 2026
Field Trip Health stock logo

Field Trip Health TSE:FTRP

Field Trip Health Ltd. engages in the development and delivery of psychedelic- assisted therapies in North America. The company operates Field Trip Health Centres that provide psychedelic therapies; offers Field Trip Digital apps; operates Field Trip Discovery, a drug development division that develops the next generation of psychedelic molecules; and provides ketamine-assisted therapy for the treatment of depression, anxiety, addiction, and other conditions. Field Trip Health Ltd. was founded in 2008 and is headquartered in Toronto, Canada.

KDA Group stock logo

KDA Group CVE:KDA

C$0.07 -0.01 (-12.50%)
As of 02:22 PM Eastern

KDA Group Inc., together with its subsidiaries, provides solutions and services to pharmacies and pharmaceutical companies in Canada. The company operates through three segments: Pharmacy Services, Pharmaceutical Solutions, and Technology. It provides pharmacy staff replacement services, professional and continued medical training services, pharmacy re-engineering services, and pharmaceutical training services. The company also offers PREDICTIVE e-Prescriber software for assisting doctors; and KRx, a cloud-based solution that analyzes each user's prescription pattern and displays the appropriate expected medication. The company was formerly known as AlliancePharma Inc. and changed its name to KDA Group Inc. in February 2017. KDA Group Inc. was founded in 2009 and is headquartered in Thetford Mines, Canada.

Nova Leap Health stock logo

Nova Leap Health CVE:NLH

C$0.52 -0.06 (-10.34%)
As of 03:41 PM Eastern

Nova Leap Health Corp., together with its subsidiaries, provides home and home health care services in the United States and Canada. Its services include dementia care, companionship, personal and skilled nursing care, respite care, cooking and meal preparation, bathing, dressing, grooming, housekeeping, errands, transportation, and medication reminders. The company was incorporated in 2015 and is headquartered in Halifax, Canada.

Synthetic Biologics stock logo

Synthetic Biologics NYSEAMERICAN:SYN

Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Synthetic Biologics, Inc. is headquartered in Rockville, Maryland.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas